Whitepaper: Drug repurposing strategies to shorten timelines
Posted: 24 November 2021 | Thermo Fisher Scientific | No comments yet
This whitepaper explores drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
The high attrition rate of new chemical entities and de novo drugs in clinical phases has resulted in the rise of the R&D costs and forced the industry to look at drug repurposing or drug repositioning strategies. The obvious advantage of repurposing drug candidates is that their safety is likely to be established in certain dosages and in some delivery routes. Learn about:
- The drug repurposing development pathway
- The promise of repurposed drug
- CDMO support and critical role as partners.
Related content from this organisation
- ebook: Twin-screw extrusion for pharmaceutical applications
- Biopharmaceuticals contributing to manufacturing outsourcing trend
- Biologics driving continuous bioprocessing market expansion
- Mycoplasma testing market expected to value nearly $2 million by 2031
- Drug development trends: insight from Thermo Fisher’s Anil Kane
Related topics
Biologics, Biopharmaceuticals, Bioprocessing, Drug Delivery Systems, Excipients, Formulation, Freeze Drying, Gene therapy, Good Manufacturing Practice (GMP), Ingredients, Manufacturing, Outsourcing, QA/QC, Regulation & Legislation, Research & Development (R&D), Stem Cells, Supply Chain, Vaccines
